Xiaomin Ou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xiaomin Ou has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Chaosu Hu
Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China
5 shared publications Chunying Shen
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
5 shared publicationsTingting Xu
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
5 shared publicationsHongmei Ying
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
2 shared publicationsJianhui Ding
Department of Diagnostic Radiology, Fudan University Shanghai Cancer Center, Shanghai, China
2 shared publicationsLin Kong
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
2 shared publications
Latest Publications
- Open Access
- 2 March 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (15) , 21013-21022
The role of adjuvant chemotherapy in nasopharyngeal carcinoma with bulky neck lymph nodes in the era of IMRT
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Tingting Xu1, 2, Chunying Shen1, 2, Xiaomin Ou1, 2, Xiayun He1, 2, Hongmei Ying1, 2, Chaosu Hu1, 2 1Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China 2Department of Oncology, Shanghai Medical College, Shanghai, China Correspondence to: Chaosu Hu, e-mail: hucsu62@163.com Keywords: nasopharyngeal carcinoma, locally advanced, N2–3, intensity modulated radiation therapy, adjuvant chemotherapy Received: September 18, 2015 Accepted: January 29, 2016 Published: March 02, 2016
- 2 March 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (15) , 21013-21022
Open AccessThe role of adjuvant chemotherapy in nasopharyngeal carcinoma with bulky neck lymph nodes in the era of IMRT
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Tingting Xu1, 2, Chunying Shen1, 2, Xiaomin Ou1, 2, Xiayun He1, 2, Hongmei Ying1, 2, Chaosu Hu1, 2 1Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China 2Department of Oncology, Shanghai Medical College, Shanghai, China Correspondence to: Chaosu Hu, e-mail: hucsu62@163.com Keywords: nasopharyngeal carcinoma, locally advanced, N2–3, intensity modulated radiation therapy, adjuvant chemotherapy Received: September 18, 2015 Accepted: January 29, 2016 Published: March 02, 2016
- 1 January 2016
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 27 (1) , 66-70
Cetuximab in combination with chemoradiotherapy in the treatment of recurrent and/or metastatic nasopharyngeal carcinoma
The aim of the study was to assess the efficacy and toxicity of cetuximab in the combined treatment for patients with recurrent and/or metastatic nasopharyngeal carcinoma (R/M NPC). Between March 2007 and November 2011, a total of 30 R/M NPC patients treated with comprehensive therapy including cetuximab were retrospectively enrolled. Intensity-modulated radiation therapy was delivered in recurrent disease with a median dose of 60 Gy. Chemotherapy regimens included TP/TPF (docetaxel 60–75 mg/m2 d1+DDP 25 mg/m2 d1–3±5-FU 500 mg/m2/day with 120-h infusion), GP (gemcitabine 1.0 g/m2 d1, d8+DDP 25 mg/m2 d1–3), and PC (paclitaxel 60 mg/m2/week d1+carboplatin AUC 2/week d1). Acute and late toxicities were documented by the radiation oncologists. The median age of the patients was 44 years (range 26–62). A total of 21 patients (70%) achieved response (CR+PR). The median survival time, time to progression, and 2-year overall survival were 23.6, 12.2 months, and 53.3%, respectively. Cetuximab appears to be effective and well tolerated when combined with chemoradiation therapy for the treatment of R/M NPC.
- 1 January 2016
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 27 (1) , 66-70
Cetuximab in combination with chemoradiotherapy in the treatment of recurrent and/or metastatic nasopharyngeal carcinoma
The aim of the study was to assess the efficacy and toxicity of cetuximab in the combined treatment for patients with recurrent and/or metastatic nasopharyngeal carcinoma (R/M NPC). Between March 2007 and November 2011, a total of 30 R/M NPC patients treated with comprehensive therapy including cetuximab were retrospectively enrolled. Intensity-modulated radiation therapy was delivered in recurrent disease with a median dose of 60 Gy. Chemotherapy regimens included TP/TPF (docetaxel 60–75 mg/m2 d1+DDP 25 mg/m2 d1–3±5-FU 500 mg/m2/day with 120-h infusion), GP (gemcitabine 1.0 g/m2 d1, d8+DDP 25 mg/m2 d1–3), and PC (paclitaxel 60 mg/m2/week d1+carboplatin AUC 2/week d1). Acute and late toxicities were documented by the radiation oncologists. The median age of the patients was 44 years (range 26–62). A total of 21 patients (70%) achieved response (CR+PR). The median survival time, time to progression, and 2-year overall survival were 23.6, 12.2 months, and 53.3%, respectively. Cetuximab appears to be effective and well tolerated when combined with chemoradiation therapy for the treatment of R/M NPC.
- Open Access
- 14 October 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (35) , 38381-38397
Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost
Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost
- 14 October 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (35) , 38381-38397
Open AccessTreatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost
Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost
- 1 October 2014
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 90 (2) , 261-269
Effect of Dosimetric Factors on Occurrence and Volume of Temporal Lobe Necrosis Following Intensity Modulated Radiation Therapy for Nasopharyngeal Carcinoma: A Case-Control Study
- 1 October 2014
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 90 (2) , 261-269
Effect of Dosimetric Factors on Occurrence and Volume of Temporal Lobe Necrosis Following Intensity Modulated Radiation Therapy for Nasopharyngeal Carcinoma: A Case-Control Study
- Open Access
- 1 January 2014
- Published by Asia Press in Journal of Nasopharyngeal Carcinoma
- Vol. 1 (13)
Use Of 18F-FDG PET/CT In The Diagnosis, Staging, Response Assessment And Prognosis Of Nasopharyngeal Carcinoma: An Updated Review
Use Of 18F-FDG PET/CT In The Diagnosis, Staging, Response Assessment And Prognosis Of Nasopharyngeal Carcinoma: An Updated Review
- 1 January 2014
- Published by Asia Press in Journal of Nasopharyngeal Carcinoma
- Vol. 1 (13)
Open AccessUse Of 18F-FDG PET/CT In The Diagnosis, Staging, Response Assessment And Prognosis Of Nasopharyngeal Carcinoma: An Updated Review
Use Of 18F-FDG PET/CT In The Diagnosis, Staging, Response Assessment And Prognosis Of Nasopharyngeal Carcinoma: An Updated Review
- 1 October 2012
- Published by Elsevier in Oral Oncology
- Vol. 48 (10) , 1045-1050
Treatment outcome of nasopharyngeal carcinoma with retropharyngeal lymph nodes metastasis only and the feasibility of elective neck irradiation
- 1 October 2012
- Published by Elsevier in Oral Oncology
- Vol. 48 (10) , 1045-1050
Treatment outcome of nasopharyngeal carcinoma with retropharyngeal lymph nodes metastasis only and the feasibility of elective neck irradiation
- 30 November 2011
- Published by Elsevier in Neurochemistry International
- Vol. 59 (6) , 739-748
Mitochondrial ERK plays a key role in delta-opioid receptor neuroprotection against acute mitochondrial dysfunction
- 30 November 2011
- Published by Elsevier in Neurochemistry International
- Vol. 59 (6) , 739-748
Mitochondrial ERK plays a key role in delta-opioid receptor neuroprotection against acute mitochondrial dysfunction